Conference
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Abstract
Abstract
Authors
Kuruvilla J; Gutierrez M; Shah BD; Gabrail NY; de Nully Brown P; Stone RM; Garzon R; Savona M; Siegel DS; Baz R
Volume
122
Publisher
American Society of Hematology
Publication Date
November 15, 2013
DOI
10.1182/blood.v122.21.90.90
Conference proceedings
Blood
Issue
21
ISSN
0006-4971